Transcatheter arterial chemoembolization (TACE) is a standard treatment for 21 unresectable hepatocellular carcinoma; however, it does not always result in tumor control. 22 40 41 3 42
Nevertheless, treatment outcome can be improved with monodisperse emulsions of anticancer 23 agents. In this study, the efficacy and safety of a monodisperse miriplatin-Lipiodol emulsion 24 were evaluated in Japanese white rabbits. VX2 tumor was implanted into the left liver lobe of 25 each rabbit. The animals were divided into control and experimental groups (of five animals 26 each) and respectively administered a conventional miriplatin suspension or the emulsion via 27 the left hepatic artery. Computed tomography (CT) was performed before, immediately after, 28 and two days following TACE. All rabbits were sacrificed two days after the procedure. Each 29 tumor was removed and cut in half for assessment of iodine concentration in one half by mass 30 spectroscopy and evaluation of Lipiodol accumulation and adverse events in the other half. 31 Mean Hounsfield unit (HU) values were measured using plain CT images taken before and 32 after TACE. Iodine concentration was higher in the experimental group [1100 (750-1500) 33 ppm] than in the control group [840 (660-1800) ppm]. Additionally, the HU value for the 34 experimental group was higher than that for the control group immediately after [199.6 (134.0-35 301.7) vs. 165.3 (131.4-280.5) ] and two days after [114.2 (56.1-229.8) vs. 58.3 (42.9-132.5) ] 36 TACE. Cholecystitis was observed in one rabbit in the control group. Ischemic bile duct injury 37 was not observed in any group. The results show that Lipiodol accumulation and retention in 38 VX2 tumor may be improved by using a monodisperse emulsion. Moreover, no significant 39 adverse events are associated with the use of the emulsion.
Introduction 43 Transcatheter arterial chemoembolization (TACE) is a standard of care for unresectable 44 hepatocellular carcinoma (HCC), according to the Barcelona Clinic Liver Cancer (BCLC) 45 treatment protocol. [1] The procedure consists of two steps. First, a mixture of anticancer agents 46 (doxorubicin, epirubicin, cisplatin, and miriplatin) and iodized oil (Lipiodol; Guerbet, 47 Villepinte, France) is injected through microcatheters placed in a feeding artery. Gelatin slurry 48 is subsequently injected to induce ischemia. Lipiodol emulsion may improve local tumor control. Emulsion has been prepared by manually 62 mixing two agents using a three-way stopcock without adding a surfactant. The resultant 63 polydisperse emulsion is unstable and will typically get stuck in the proximal feeding arteries, 64 thus compromising the delivery of an anticancer agent to the tumor. A solution to this problem 65 is to use a monodisperse emulsion, which can be prepared by membrane emulsification using 4 66 the following procedure. A mixture of the anticancer agent and Lipiodol (water-in-oil 67 emulsion, w/o emulsion) is pushed under constant pressure through an SPG membrane (from 68 SPG Technology Co., Ltd.), which has multiple even-sized pores. A homogenous emulsion, 69 specifically a water-in-oil-in-water (w/o/w) emulsion, can then be obtained. Clinical 70 application of this type of dispersion has been already attempted using epirubicin w/o/w 71 emulsion and promising results have been obtained.
[8] However, the process for preparing a 72 w/o/w emulsion is complex. Moreover, emulsions that are prepared using lipophilic anticancer 73 agents are more stable since their affinity for Lipiodol is higher than that of hydrophilic agents. 74 Miriplatin is a lipophilic platinum derivative. Miriplatin (Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan) suspension was 84 prepared using 60 mg miriplatin powder and 3 mL Lipiodol. In order to prepare the emulsion, 85 the suspension was pushed through a 20-µm hydrophilic SPG membrane (SPG Technology 86 Co., Ltd., Miyazaki, Japan) into an outer aqueous phase using a syringe pump 87 (https://dx.doi.org/10.17504/protocols.io.6edhba6). PEG-60 hydrogenated castor oil (HCO 60; 88 Nikko Chemicals Co., Ltd., Tokyo, Japan) was used as a surfactant in the formulation. HCO 5 89 60 (0.8 %) was added to NaCl solution (0.45 %w/v) to obtain a mixture that was used as the 90 outer aqueous phase. Droplet size was measured by microscopy at 100× magnification. Kernel 91 density estimation was performed to estimate the distribution of droplet diameter.
92
Animal experiment 93 The study was carried out in strict accordance with the relevant guidelines and acts in Medical Systems, Tochigi, Japan) was performed prior to TACE. The contrast medium 104 (iopamidol, 300 mg I/mL; Fuji Pharma Co., Ltd., Tokyo, Japan) was intravenously injected at 105 2 mL/kg at a rate of 0.2 mL/s into the animals. Quadriphasic scan was performed at 20, 40, 63, 106 and 118 s after the injection. The scanning parameters used were as follows: collimation 107 thickness, 80 × 0.5 mm; rotation speed, 0.35 s; helical pitch, 0.738; tube voltage, 80 kVp; and 108 tube current, automatic exposure control. 109 TACE was performed under general anesthesia, which was induced using a subcutaneous 110 injection of medetomidine hydrochloride (0.1 mg/kg) and ketamine hydrochloride (25 mg/kg) 111 before moving to angio suite. Anesthesia was maintained by inhalation of 2-2.5 % isoflurane 112 in angio suite. Each rabbit was monitored during the procedure using an electrocardiograph 6 113 and a pulse oximeter. The common femoral artery was surgically exposed, into which a 4-F 114 introducer sheath (Medikit Co., Ltd., Tokyo, Japan) was inserted. The celiac artery was 115 cannulated with a 4-F C2 diagnostic catheter (Medikit Co., Ltd.). Next, a 2-F microcatheter 116 (Gold Crest Neo; HI-LEX, Takarazuka, Japan) was coaxially advanced into the left hepatic 117 artery, after which 0.1 mL of either the suspension or emulsion was injected under fluoroscopic 118 guidance. A plain CT scan was taken immediately after the procedure. 119 All the rabbits were euthanized two days after TACE by injecting pentobarbital sodium 120 (100mg/kg) intravenously. Dynamic contrast-enhanced CT scanning was performed prior to 121 sacrifice by following the same protocol as before TACE. The tumor was extracted and cut in 122 half: one half was used for pathological evaluation, whereas the other half was evaluated for 123 its iodine content by mass spectroscopy. compressed to obtain a JPEG image with a resolution of 1920 × 984 pixels. Lipiodol 137 accumulation was evaluated using the HSV model, which defines color space by three 138 parameters: hue, saturation, and value. Lesions without lipid were bluish in color. An area with 139 a 'hue' value of more than 55 and less than 65 was digitally subtracted from the digitized 140 specimen by setting 'value' to be zero. The remaining area was considered to be the region of 141 Lipiodol accumulation. The extent of Lipiodol accumulation was evaluated using 'saturation'. 142 Source codes were written in Python (Anaconda 4.6.14; Anaconda, Inc., Austin, TX, USA) 143 using Jupyter Notebook, whereas cv2 module was used for image processing as described 
Results
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A monodisperse s/o/w emulsion containing miriplatin was successfully formulated with 160 a mean diameter of 62.0 ± 6.42 µm (Fig 1) . Kernel density estimation showed that the mode 161 droplet size was 60.0 µm. All experimental procedures were successfully performed. 162 The mean body weights of the rabbits were 2.6 ± 0.1 and 2.7 ± 0.1 kg in the control and 163 experimental groups, respectively. Tumor diameter was 14.3 ± 5.6 mm in the control group 164 and 15.4 ± 3.0 mm in the experimental group. All tumors were confirmed to be in the left lobe 165 by CT scan prior to performing TACE. In the experimental group, Lipiodol accumulation in the gallbladder was observed in four 205 rabbits immediately after TACE; however, washout was observed in all rabbits and 206 cholecystitis was not observed. Conversely, in the control group, Lipiodol accumulation was 207 observed in three rabbits after TACE and washout was not observed in one animal, in which 208 cholecystitis ensued (Fig 7) . Bile duct injury and biloma were not observed in either group. Lipiodol reach the tumor microcirculation as separate components, which does not allow 229 Lipiodol to work as an efficient carrier. Miriplatin may be superior to other agents since it will 230 be delivered to the tumor combined to Lipiodol. Moreover, compared to epirubicin or cisplatin, 231 miriplatin induces lesser vascular damage. [11, 12] The results of a previous randomized control trial showed that the antitumor effect of miriplatin 238 is equal or superior to that of epirubicin or cisplatin. However, it is also reported that ingredients are administered to both groups of rabbits. Additionally, the two-day period from 13 278 TACE to animal sacrifice was too short for effective evaluation of antitumor effect. It has been 279 shown that, in VX2-tumor-bearing rabbits, the difference in the concentration of an anticancer 280 agent between the tumor and normal liver parenchyma peaks in approximately three days after 281 TACE is performed when an emulsion prepared using SPG membrane is administered to the 282 rabbits.
[20] The main purpose of the present study was to evaluate the difference in Lipiodol 283 distribution following treatment with conventional miriplatin suspension or miriplatin s/o/w 284 emulsion. Thus, the observational period in future experiments should be longer. Furthermore, 285 the droplet size of the emulsion should be considered. For instance, in the present study, an 286 SPG membrane with a pore size of 20 µm was used to obtain an emulsion with a peak droplet 287 diameter of 60 µm. This was because a previous clinical study on the efficacy of an epirubicin 288 w/o/w emulsion revealed that local tumor control was better when droplet size 70 µm than 289 when it was 30 µm.
[21] Emulsions with small-sized droplets can enter microcirculation 290 without being trapped, which indicates that droplet sizes as large as 70 µm are recommended. 291 However, the data on the vessel diameters of rabbits are scarce and optimal target droplet size 292 for rabbits should be determined by further investigation. 293 In conclusion, Lipiodol accumulation and retention in VX2 tumor may be improved by using 294 a monodisperse emulsion, which is associated with no significant adverse events. 
